Part 5/9:
Despite the promising data, it’s essential to recognize that both companies are still in the early stages of development. Thus, potential investors should weigh the risks carefully.
AbbVie’s Strategic Acquisition
AbbVie also captured attention with its acquisition of Stemcentrx for $5.8 billion, primarily for its lead candidate, Rova-T. This drug is intended for treating small cell lung cancer, a particularly aggressive form of the disease.